20 April 2023
Biodexa Pharmaceuticals PLC
("Biodexa" or the "Company")
Exercise of Pre-Funded Warrants and Issue of Equity
Total Voting Rights
Biodexa Pharmaceuticals PLC (AIM: BDRX; Nasdaq: BDRX), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has yesterday issued to an investor 6,275,465 new ordinary shares of £0.02 each in the Company ("New Ordinary Shares"), pursuant to exercise notices in respect of 1,255,093 Pre-Funded Warrants received on 18 April 2023. These Pre-Funded Warrants were exercised at US$0.0004 per Pre-Funded Warrant for gross proceeds of US$502.04. Further details are set out in the Company's circular dated 7 March 2023.
Admission and total voting rights
Application has been made to the London Stock Exchange plc for the admission to trading on AIM of the New Ordinary Shares, which is expected to become effective and dealings commence at 8.00 a.m. on or around 25 April 2023 ("Admission"). The New Ordinary Shares will rank pari passu with the existing ordinary shares.
The Company's enlarged issued share capital on Admission will comprise 94,629,412 ordinary shares, each with voting rights. The Company does not hold any shares in treasury. From Admission, expected to take place on 25 April 2023, this figure of 94,629,412 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Unless otherwise defined, capitalised terms used in this announcement have the same meanings as ascribed to them in the Company's circular dated 7 March 2023.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014, as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended.
For more information, please contact:
Biodexa Pharmaceuticals PLC |
| |
Stephen Stamp, CEO, CFO |
| |
Tel: +44 (0)29 2048 0180 |
| |
www.biodexapharma.com |
| |
|
| |
Strand Hanson Limited (Nominated Adviser and Broker) |
| |
James Dance / Matthew Chandler / Rob Patrick |
| |
Tel: +44 (0)20 7409 3494 |
| |
|
| |
IFC Advisory Limited (Financial PR and UK Investor Relations) |
| |
Tim Metcalfe / Graham Herring |
| |
Tel: +44 (0)20 3934 6630 |
| |
Email: midatech@investor-focus.co.uk |
| |
|
| |
Edison Group (US Investor Relations) Alyssa Factor Tel: +1 (860) 573 9637 Email: afactor@edisongroup.com
|
| |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.